Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Non-Current Assets (2016 - 2025)

IGC Pharma has reported Non-Current Assets over the past 15 years, most recently at $7.7 million for Q3 2025.

  • Quarterly Non-Current Assets rose 26.47% to $7.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $7.7 million through Sep 2025, up 26.47% year-over-year, with the annual reading at $5.9 million for FY2025, 5.58% down from the prior year.
  • Non-Current Assets was $7.7 million for Q3 2025 at IGC Pharma, up from $5.8 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $12.4 million in Q1 2021 and troughed at $5.8 million in Q2 2025.
  • The 5-year median for Non-Current Assets is $10.6 million (2023), against an average of $9.3 million.
  • Year-over-year, Non-Current Assets plummeted 42.15% in 2024 and then increased 26.47% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $12.1 million in 2021, then dropped by 11.08% to $10.7 million in 2022, then decreased by 28.37% to $7.7 million in 2023, then fell by 21.48% to $6.0 million in 2024, then grew by 28.41% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Non-Current Assets are $7.7 million (Q3 2025), $5.8 million (Q2 2025), and $5.9 million (Q1 2025).